ZLAB250117C45000
- 0.00
- 0.000.00%
Zai Lab Newsroom
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $29
Bank of America Securities Keeps Their Buy Rating on Zai Lab (ZLAB)
CITIC: Maintain ZAI LAB (09688) "Outperform Industry" rating, Target Price 28.1 Hong Kong dollars.
Zaiding Pharmaceutical (09688.HK): Introduces POVETACICEPT to enter the domestic IGA nephrology market
Hong Kong stocks movement | ZAI LAB (09688) rose over 5%. Institutions are bullish on its commercialization and innovative research and development, initially rating it as 'Buy'.
GF SEC: Assigning a "Buy" rating to ZAI LAB (09688) as research and development enters a new phase of globalization.
Zaiding Pharmaceutical (9688.HK): Development ushered in an inflection point, R&D entered a new stage of globalization
Jefferies Maintains Zai Lab(ZLAB.US) With Buy Rating, Raises Target Price to $50
Zai Lab Analyst Ratings
Leerink Partners Maintains Zai Lab(ZLAB.US) With Buy Rating, Raises Target Price to $72
Analysts' Top Healthcare Picks: Universal Health (UHS), Zai Lab (ZLAB)
[Brokerage Focus] Guotai Junan International reiterated a 'buy' rating on Zai Lab (09688), the company's global equity innovative drug pipeline is progressing smoothly.
Zaiding Pharmaceutical (09688.HK): DLL3 ADC data is positive and recent catalysts are abundant
U.S. stock market anomaly: zai lab surged 10% before the market opened and received a target price increase from jpmorgan.
Zaiding Pharmaceutical (9688.HK): Excellent initial efficacy and safety data of DLL3ADC
Zai Lab Is Maintained at Overweight by JP Morgan
Zai Lab Analyst Ratings
Jefferies Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $38
Jefferies Maintains Zai Lab(ZLAB.US) With Buy Rating, Cuts Target Price to $38
Strong Buy Rating for Zai Lab: Outperforming Vyvgart Sales and Promising Global Pipeline Fuel Optimism